MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

Начало・Списък с акции・Prothena Corp PLC

Prothena Corp PLC

Затворен

СекторЗдравеопазване

6.4 0.16

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.32

Максимум

6.48

Ключови измерители
By Trading Economics
Приходи	-2.2M -60M
Продажби	705K 2.8M
Марж на печалбата	-2,128.536
Служители	163
EBITDA	-682K -65M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+242.81% upside

Дивиденти
By Dow Jones
Следващи печалби	7.08.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-400M 346M
Предишно отваряне	6.24
Предишно затваряне	6.4

Настроения в новините

By Acuity

84%

16%

355 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

N/A / 7.35 Подкрепа & съпротива

Prothena Corp PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.07.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

FCC Approves U.S. Cellular Sale to T-Mobile

11.07.2025 г., 17:28 ч. UTC

Значими двигатели на пазара

SharpLink Gaming Gains on Ethereum Purchase

11.07.2025 г., 16:57 ч. UTC

Печалби

BASF Cuts Outlook on Global Economy Uncertainty

13.07.2025 г., 23:54 ч. UTC

Пазарно говорене

Oil Edges Higher Amid Supply Disruption Worries -- Market Talk

13.07.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

13.07.2025 г., 23:49 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.07.2025 г., 23:40 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

13.07.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Advances Amid Rising Trade Tensions -- Market Talk

13.07.2025 г., 23:39 ч. UTC

Пазарно говорене

China's Growth Momentum Likely Slowed in 2Q -- Market Talk

13.07.2025 г., 23:16 ч. UTC

Печалби

China Shenhua Energy 1H 2024 Net Was CNY32.8B>1088.HK

13.07.2025 г., 23:16 ч. UTC

Печалби

China Shenhua Energy: Drop in Coal Prices Weighed on Results >1088.HK

13.07.2025 г., 23:16 ч. UTC

Печалби

China Shenhua Energy Sees 1H Net CNY25.6B-Net CNY27.6B >1088.HK

13.07.2025 г., 23:13 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.07.2025 г., 23:13 ч. UTC

Пазарно говорене

Ryman Healthcare Could Be Turning a Corner -- Market Talk

13.07.2025 г., 11:00 ч. UTC

Придобивния, сливания и поглъщания

The Private-Equity Maneuver Allowing More Investors to Cash Out -- WSJ

12.07.2025 г., 02:24 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11.07.2025 г., 19:46 ч. UTC

Придобивния, сливания и поглъщания

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11.07.2025 г., 19:45 ч. UTC

Пазарно говорене

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11.07.2025 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11.07.2025 г., 18:18 ч. UTC

Пазарно говорене

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11.07.2025 г., 17:35 ч. UTC

Пазарно говорене

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11.07.2025 г., 17:26 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11.07.2025 г., 16:53 ч. UTC

Пазарно говорене

Crude Futures Add to Early Gains -- Market Talk

11.07.2025 г., 16:42 ч. UTC

Печалби

BASF Cuts Outlook on Global Economic Uncertainty

11.07.2025 г., 16:08 ч. UTC

Пазарно говорене

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11.07.2025 г., 16:05 ч. UTC

Печалби

BASF Will Publish Half-Year Results on July 30

Сравнение с други в отрасъла

Ценова промяна

Prothena Corp PLC Прогноза

Ценова цел

By TipRanks

242.81% нагоре

12-месечна прогноза

Среден 21.94 USD 242.81%

Висок 81 USD

Нисък 4 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Prothena Corp PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Prothena Corp PLC през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 7.35Подкрепа & съпротива

All events are bearish.

Настроение

By Acuity

355 / 376 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.